Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

intellia therapeutics inc. - NTLA

NTLA

Close Chg Chg %
9.74 -0.03 -0.26%

Closed Market

9.71

-0.03 (0.26%)

Volume: 3.35M

Last Updated:

Jan 15, 2025, 4:00 PM EDT

Trade Now

Company Overview: intellia therapeutics inc. - NTLA

NTLA Key Data

Open

$10.24

 Day Range

9.64 - 10.31

52 Week Range

9.59 - 34.87

 Market Cap

$992.01M

Shares Outstanding

101.85M

 Public Float

99.79M

Beta

1.83

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.45

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.88M

  

NTLA Performance

1 Week
 
 -4.56%
 
1 Month
 
 -24.53%
 
3 Months
 
 -53.82%
 
1 Year
 
 -64.82%
 
5 Years
 
 -33.46%
 

NTLA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About intellia therapeutics inc. - NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

NTLA At a Glance

Intellia Therapeutics, Inc.
40 Erie Street
Cambridge, Massachusetts 02139
Phone 1-857-285-6200 Revenue 36.28M
Industry Biotechnology Net Income -481,192,000.00
Sector Health Technology Employees 526
Fiscal Year-end 12 / 2024
View SEC Filings

NTLA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 74.613
Price to Book Ratio 2.70
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.772
Enterprise Value to Sales 52.646
Total Debt to Enterprise Value 0.06

NTLA Efficiency

Revenue/Employee 68,963.878
Income Per Employee -914,813.688
Receivables Turnover 0.995
Total Asset Turnover 0.026

NTLA Liquidity

Current Ratio 8.665
Quick Ratio 8.665
Cash Ratio 7.918

NTLA Profitability

Gross Margin 75.256
Operating Margin -1,420.513
Pretax Margin -1,326.511
Net Margin -1,326.511
Return on Assets -34.114
Return on Equity -42.104
Return on Total Capital -41.286
Return on Invested Capital -38.549

NTLA Capital Structure

Total Debt to Total Equity 10.984
Total Debt to Total Capital 9.897
Total Debt to Total Assets 8.866
Long-Term Debt to Equity 9.213
Long-Term Debt to Total Capital 8.301
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Intellia Therapeutics Inc. - NTLA

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
57.99M 33.05M 52.12M 36.27M
Sales Growth
+34.55% -43.01% +57.69% -30.40%
Cost of Goods Sold (COGS) incl D&A
- 6.89M 7.57M 8.98M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.31M 6.89M 7.57M 8.98M
Depreciation
6.31M 6.89M 7.57M 8.98M
Amortization of Intangibles
- - - -
-
COGS Growth
- - +9.88% +18.54%
-
Gross Income
- 26.16M 44.55M 27.30M
Gross Income Growth
- - +70.28% -38.72%
-
Gross Profit Margin
- +79.15% +85.47% +75.26%
2020 2021 2022 2023 5-year trend
SG&A Expense
188.27M 294.01M 502.71M 542.59M
Research & Development
144.10M 222.92M 412.41M 426.09M
Other SG&A
44.17M 71.10M 90.31M 116.50M
SGA Growth
+30.85% +56.17% +70.98% +7.93%
Other Operating Expense
- - - -
-
Unusual Expense
- - 13.48M 100.00K
-
EBIT after Unusual Expense
(136.58M) (267.85M) (471.65M) (515.39M)
Non Operating Income/Expense
2.35M (42.00K) (2.54M) 34.20M
Non-Operating Interest Income
2.35M 1.28M 8.54M 49.83M
Equity in Earnings of Affiliates
- (1.32M) (11.08M) (15.63M)
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(134.23M) (267.89M) (474.19M) (481.19M)
Pretax Income Growth
-34.86% -99.58% -77.01% -1.48%
Pretax Margin
-231.46% -810.49% -909.78% -1,326.51%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (1.32M) (11.08M) (15.63M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(134.23M) (267.89M) (474.19M) (481.19M)
Minority Interest Expense
- - - -
-
Net Income
(134.23M) (267.89M) (474.19M) (481.19M)
Net Income Growth
-34.86% -99.58% -77.01% -1.48%
Net Margin Growth
-231.46% -810.49% -909.78% -1,326.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(134.23M) (267.89M) (474.19M) (481.19M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(134.23M) (267.89M) (474.19M) (481.19M)
EPS (Basic)
-2.3975 -3.7788 -6.1605 -5.4207
EPS (Basic) Growth
-13.81% -57.61% -63.03% +12.01%
Basic Shares Outstanding
55.99M 70.89M 76.97M 88.77M
EPS (Diluted)
-2.3975 -3.7788 -6.1605 -5.4207
EPS (Diluted) Growth
-13.81% -57.61% -63.03% +12.01%
Diluted Shares Outstanding
55.99M 70.89M 76.97M 88.77M
EBITDA
(130.27M) (260.96M) (450.59M) (506.31M)
EBITDA Growth
-29.26% -100.32% -72.67% -12.37%
EBITDA Margin
-224.63% -789.52% -864.51% -1,395.77%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 54.739
Number of Ratings 28 Current Quarters Estimate -1.357
FY Report Date 03 / 2025 Current Year's Estimate -5.149
Last Quarter’s Earnings -1.35 Median PE on CY Estimate N/A
Year Ago Earnings -5.302 Next Fiscal Year Estimate -5.184
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 25 17
Mean Estimate -1.36 -1.27 -5.15 -5.18
High Estimates -1.09 -0.98 -3.09 -3.21
Low Estimate -1.61 -1.49 -6.78 -7.17
Coefficient of Variance -9.91 -12.31 -15.52 -18.64

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 21 21
OVERWEIGHT 2 2 3
HOLD 6 6 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Buy Overweight

Insider Actions for Intellia Therapeutics Inc. - NTLA

Date Name Shares Transaction Value
Jan 6, 2025 John M. Leonard President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 John M. Leonard President and CEO; Director 967,922 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Laura Sepp-Lorenzino EVP, Chief Scientific Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 Laura Sepp-Lorenzino EVP, Chief Scientific Officer 86,354 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 David Lebwohl EVP, Chief Medical Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 6, 2025 David Lebwohl EVP, Chief Medical Officer 97,223 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 25, 2024 Edward J. Dulac EVP, Chief Financial Officer 66,324 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 25, 2024 Edward J. Dulac EVP, Chief Financial Officer 96,219 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 4, 2024 Michael P. Dube VP, PAO and Interim PFO 49,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 4, 2024 Eliana Clark EVP, Chief Technical Officer 71,470 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.93 per share 1,638,807.10
Jun 21, 2024 Frank A. G. M. Verwiel Director 17,948 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25 per share 448,700.00
Jun 18, 2024 Brian M. Goff Director 22,297 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 18, 2024 Brian M. Goff Director 15,409 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 James Basta EVP, General Counsel 81,571 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.99 per share 2,691,027.29
Mar 6, 2024 James Basta EVP, General Counsel 46,752 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 James Basta EVP, General Counsel 83,868 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Glenn Goddard EVP, Chief Financial Officer 41,316 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Glenn Goddard EVP, Chief Financial Officer 69,213 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Eliana Clark EVP, Chief Technical Officer 71,470 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.99 per share 2,357,795.30
Mar 6, 2024 Eliana Clark EVP, Chief Technical Officer 45,072 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Intellia Therapeutics Inc. in the News